5 results on '"Zarko Alfirevic"'
Search Results
2. Cohort profile: Improved Pregnancy Outcomes via Early Detection (IMPROvED), an International Multicentre Prospective Cohort [version 3; peer review: 2 approved]
- Author
-
Kate Navaratnam, Louise C. Kenny, Darina Sheehan, Zarko Alfirevic, Christian Gluud, Philip N. Baker, Marius Kublickas, Robin Tuytten, Johannes J. Duvekot, Boel Niklasson, Pensee Wu, Caroline B. van den Berg, Ali S. Khashan, Karolina Kublickiene, Gillian M. Maher, and Fergus P. McCarthy
- Subjects
Cohort profile ,preeclampsia ,biobank ,clinical data ,eng ,Medicine - Abstract
Background Improved Pregnancy Outcomes via Early Detection (IMPROvED) is a multi-centre, European phase IIa clinical study. The primary aim of IMPROvED is to enable the assessment and refinement of innovative prototype preeclampsia risk assessment tests based on emerging biomarker technologies. Here we describe IMPROvED’s profile and invite researchers to collaborate. Methods A total of 4,038 low-risk nulliparous singleton pregnancies were recruited from maternity units in Ireland (N=1,501), United Kingdom (N=1,108), The Netherlands (N=810), and Sweden (N=619) between November 2013 to August 2017. Participants were interviewed by a research midwife at ~11 weeks (optional visit), ~15 weeks, ~20 weeks, ~34 weeks’ gestation (optional visit), and postpartum (within 72-hours following delivery). Findings to date Clinical data included information on maternal sociodemographic, medical history, and lifestyle factors collected at ~15 weeks’ gestation, and maternal measurements, collected at each study visit. Biobank samples included blood, urine, and hair collected at each study visit throughout pregnancy in all units plus umbilical cord/blood samples collected at birth in Ireland and Sweden. A total of 74.0% (N=2,922) had an uncomplicated pregnancy, 3.1% (N=122) developed preeclampsia, 3.6% (N=143) had a spontaneous preterm birth, and 10.5% (N=416) had a small for gestational age baby. We evaluated a panel of metabolite biomarkers and a panel of protein biomarkers at 15 weeks and 20 weeks’ gestation for preeclampsia risk assessment. Their translation into tests with clinical application, as conducted by commercial entities, was hampered by technical issues and changes in test requirements. Work on the panel of proteins was abandoned, while work on the use of metabolite biomarkers for preeclampsia risk assessment is ongoing. Future plans In accordance with the original goals of the IMPROvED study, the data and biobank are now available for international collaboration to conduct high quality research into the cause and prevention of adverse pregnancy outcomes.
- Published
- 2024
- Full Text
- View/download PDF
3. Protocol for the development of a tool (INSPECT-SR) to identify problematic randomised controlled trials in systematic reviews of health interventions
- Author
-
Elizabeth Loder, Jill Alison Hayden, David Torgerson, Tianjing Li, Wentao Li, Rui Wang, Ben W Mol, Lisa Bero, Jamie J Kirkham, Lisa Parker, Mike Clarke, Jo C Dumville, Calvin Heal, Lyle Gurrin, Andreas Lundh, Madelon van Wely, Toby Lasserson, Alison Avenell, Neil E O'Connell, Andrew Grey, Jack Wilkinson, George A Antoniou, Kylie Elizabeth Hunter, Patrick Dicker, Zarko Alfirevic, Ella Flemyng, Sarah Lensen, Emma Sydenham, Ginny Barbour, Emily Lam, Gideon Meyerowitz-Katz, James Heathers, Nicholas J L Brown, John Carlisle, Steph Grohmann, Barbara K Redman, Lene Seidler, and Kyle A Sheldrick
- Subjects
Medicine - Abstract
Introduction Randomised controlled trials (RCTs) inform healthcare decisions. It is now apparent that some published RCTs contain false data and some appear to have been entirely fabricated. Systematic reviews are performed to identify and synthesise all RCTs that have been conducted on a given topic. While it is usual to assess methodological features of the RCTs in the process of undertaking a systematic review, it is not usual to consider whether the RCTs contain false data. Studies containing false data therefore go unnoticed and contribute to systematic review conclusions. The INveStigating ProblEmatic Clinical Trials in Systematic Reviews (INSPECT-SR) project will develop a tool to assess the trustworthiness of RCTs in systematic reviews of healthcare-related interventions.Methods and analysis The INSPECT-SR tool will be developed using expert consensus in combination with empirical evidence, over five stages: (1) a survey of experts to assemble a comprehensive list of checks for detecting problematic RCTs, (2) an evaluation of the feasibility and impact of applying the checks to systematic reviews, (3) a Delphi survey to determine which of the checks are supported by expert consensus, culminating in, (4) a consensus meeting to select checks to be included in a draft tool and to determine its format and (5) prospective testing of the draft tool in the production of new health systematic reviews, to allow refinement based on user feedback. We anticipate that the INSPECT-SR tool will help researchers to identify problematic studies and will help patients by protecting them from the influence of false data on their healthcare.Ethics and dissemination The University of Manchester ethics decision tool was used, and this returned the result that ethical approval was not required for this project (30 September 2022), which incorporates secondary research and surveys of professionals about subjects relating to their expertise. Informed consent will be obtained from all survey participants. All results will be published as open-access articles. The final tool will be made freely available.
- Published
- 2024
- Full Text
- View/download PDF
4. Cohort profile: Improved Pregnancy Outcomes via Early Detection (IMPROvED), an International Multicentre Prospective Cohort [version 2; peer review: 2 approved]
- Author
-
Kate Navaratnam, Louise C. Kenny, Darina Sheehan, Zarko Alfirevic, Christian Gluud, Philip N. Baker, Marius Kublickas, Robin Tuytten, Johannes J. Duvekot, Boel Niklasson, Pensee Wu, Caroline B. van den Berg, Ali S. Khashan, Karolina Kublickiene, Gillian M. Maher, and Fergus P. McCarthy
- Subjects
Cohort profile ,preeclampsia ,biobank ,clinical data ,eng ,Medicine - Abstract
Background Improved Pregnancy Outcomes via Early Detection (IMPROvED) is a multi-centre, European phase IIa clinical study. The primary aim of IMPROvED is to enable the assessment and refinement of innovative prototype preeclampsia risk assessment tests based on emerging biomarker technologies. Here we describe IMPROvED’s profile and invite researchers to collaborate. Methods A total of 4,038 low-risk nulliparous singleton pregnancies were recruited from maternity units in Ireland (N=1,501), United Kingdom (N=1,108), The Netherlands (N=810), and Sweden (N=619) between November 2013 to August 2017. Participants were interviewed by a research midwife at ~11 weeks (optional visit), ~15 weeks, ~20 weeks, ~34 weeks’ gestation (optional visit), and postpartum (within 72-hours following delivery). Findings to date Clinical data included information on maternal sociodemographic, medical history, and lifestyle factors collected at ~15 weeks’ gestation, and maternal measurements, collected at each study visit. Biobank samples included blood, urine, and hair collected at each study visit throughout pregnancy in all units plus umbilical cord/blood samples collected at birth in Ireland and Sweden. A total of 74.0% (N=2,922) had an uncomplicated pregnancy, 3.1% (N=122) developed preeclampsia, 3.6% (N=143) had a spontaneous preterm birth, and 10.5% (N=416) had a small for gestational age baby. We evaluated a panel of metabolite biomarkers and a panel of protein biomarkers at 15 weeks and 20 weeks’ gestation for preeclampsia risk assessment. Their translation into tests with clinical application, as conducted by commercial entities, was hampered by technical issues and changes in test requirements. Work on the panel of proteins was abandoned, while work on the use of metabolite biomarkers for preeclampsia risk assessment is ongoing. Future plans In accordance with the original goals of the IMPROvED study, the data and biobank are now available for international collaboration to conduct high quality research into the cause and prevention of adverse pregnancy outcomes.
- Published
- 2024
- Full Text
- View/download PDF
5. Preterm prelabour rupture of membranes before 23 weeks’ gestation: prospective observational study
- Author
-
Goodfellow, Laura, primary, Care, Angharad, additional, Curran, Ciara, additional, Roberts, Devender, additional, Turner, Mark A, additional, Knight, Marian, additional, and Zarko, Alfirevic, additional
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.